Related Experiment Video

Updated: Aug 1, 2026

Isolating Potentiated Hsp104 Variants Using Yeast Proteinopathy Models
08:44

Isolating Potentiated Hsp104 Variants Using Yeast Proteinopathy Models

Published on: November 11, 2014

[Research on myasthenia gravis in children with HLA supratype]

X G Zhang1

  • 1HLA Laboratory, Beijing Pediatrics Institute.

Zhonghua Shen Jing Jing Shen Ke Za Zhi = Chinese Journal of Neurology and Psychiatry
|December 1, 1992
PubMed

Insights

Myasthenia Gravis (MG) in children is strongly linked to specific HLA antigens, particularly HLA-A2, Bw46, and DRw9. These findings offer insights into the genetic factors influencing MG susceptibility in pediatric populations.

Area of Science:

  • Immunogenetics
  • Pediatric Neurology
  • Autoimmune Diseases

Background:

  • Myasthenia Gravis (MG) is an autoimmune disorder affecting neuromuscular junctions.
  • Genetic factors, particularly Human Leukocyte Antigen (HLA) genes, are implicated in MG pathogenesis.
  • Previous studies have shown associations between specific HLA types and MG in various populations.

Purpose of the Study:

  • To investigate the association of HLA antigens (Class I, II, and III) with childhood Myasthenia Gravis.
  • To identify potential genetic markers for MG susceptibility and protection in pediatric patients.

Main Methods:

  • Human Leukocyte Antigen (HLA) typing was performed on 38 pediatric MG patients.
  • Statistical analysis was used to determine the relative risk associated with specific HLA antigens.

Main Results:

  • Significant associations were found between MG and HLA-A2 (Relative Risk [RR] = 3.60), Bw46 (RR = 8.18), and DRw9 (RR = 4.60).
  • No significant association was observed with C4 and Bf antigens.
  • HLA-Aw19 appeared to be a protective factor against MG.

Conclusions:

  • Specific HLA antigens (HLA-A2, Bw46, DRw9) are significantly associated with childhood Myasthenia Gravis.
  • The genetic associations in this cohort of Chinese pediatric MG patients resemble findings in Hong Kong Chinese but differ from Caucasian data.
  • HLA-Aw19 may confer protection against MG in this population.

More Related Videos

Antigenic Liposomes for Generation of Disease-specific Antibodies10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis05:55

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Published on: December 1, 2023

Related Concept Videos

Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...